Abstract
Analysis of Fhit expression in stages of breast cancer progression
Highlights
Background and purposeAkt-1 is a serine/threonineprotein kinase that regulates growth factor-dependent cell proliferation and survival
After the analysis of the HRAS1 MVR sequences and the length polymorphism typing in the healthy control population and the affected patients, we have observed that 20% of breast cancer patients had at least one rare HRAS1 allele compared to 6.42% of HRAS1 alleles in the control population (χ2, P = 0.0037)
In our recent report [1] a high frequency (33%) of germline BRCA2 mutations was detected among Hungarian male breast cancer cases without family history
Summary
Akt-1 is a serine/threonineprotein kinase that regulates growth factor-dependent cell proliferation and survival. Activated-Akt-1 causes Bcl-2 release from the BAD:Bcl-2 inactive complex. Bcl is able to prevent apoptosis, as a downstream effector of Akt-1, and can delay cell-cycle progression. Akt-1 is over-expressed in breast cancer cell lines and tumours, while Bcl-2 has been related with tumour survival and drug resistance in vitro and to an ER+/well differentiated sub-group of tumours, in vivo. Since endocrine treatment effectiveness could be due to activation of the apoptotic program, we wanted to investigate the expression and relationship between these factors as well as other variables (C-erbB-2, ER, and S-phase)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
